Allakos Inc (NAS:ALLK)
$ 1.3 0.04 (3.17%) Market Cap: 112.57 Mil Enterprise Value: 59.75 Mil PE Ratio: 0 PB Ratio: 1.55 GF Score: 28/100

Allakos Inc. - Special Call Transcript

May 07, 2019 / 09:00PM GMT
Release Date Price: $39.09 (-2.15%)
Operator

Good day, and welcome to the conference call hosted by Allakos. Today's conference is being recorded.

At this time, I would like to turn the conference over to Mr. Robert Alexander, CEO of Allakos. Please go ahead, sir.

Robert Alexander
Allakos Inc. - President, CEO & Director

Thank you. I'd like to thank everybody for joining our call today. Here with me in the room, I have Adam Tomasi, our CFO; Henrik Rasmussen, our Chief Medical Officer; and Drs. Foster and Anesi who are principal investigators for our conjunctivitis study.

Before we jump into the presentation, a reminder that we will be making forward-looking statements so please refer to our SEC filings for a discussion of risk factors.

Okay. On the next slide is the agenda for today. So I will be going over a little bit of background on AK002, and then I'll turn it over to Henrik to review our clinical programs to-date. And then we will turn it over to Drs. Foster and Anesi to run through the data from our conjunctivitis study. And following that, we'll go into a Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot